Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) Operating Margin (2016 - 2025)

Historic Operating Margin for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to 1.43%.

  • Ptc Therapeutics' Operating Margin rose 291300.0% to 1.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 43.61%, marking a year-over-year increase of 624300.0%. This contributed to the annual value of 37.5% for FY2024, which is 93600.0% up from last year.
  • Latest data reveals that Ptc Therapeutics reported Operating Margin of 1.43% as of Q3 2025, which was up 291300.0% from 19.54% recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' Operating Margin peaked at 82.5% during Q1 2025, and registered a low of 119.67% during Q4 2022.
  • For the 5-year period, Ptc Therapeutics' Operating Margin averaged around 45.65%, with its median value being 54.58% (2022).
  • Its Operating Margin has fluctuated over the past 5 years, first soared by 1644900bps in 2021, then crashed by -780700bps in 2024.
  • Quarter analysis of 5 years shows Ptc Therapeutics' Operating Margin stood at 51.28% in 2021, then tumbled by -133bps to 119.67% in 2022, then surged by 102bps to 1.9% in 2023, then crashed by -4119bps to 76.18% in 2024, then skyrocketed by 102bps to 1.43% in 2025.
  • Its Operating Margin stands at 1.43% for Q3 2025, versus 19.54% for Q2 2025 and 82.5% for Q1 2025.